Clinical trial
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel…
NCT00457067 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00457067 |
|---|---|
| Title | Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation |
| Official title | Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Telangiectasia |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 5 |
| Start date | Mar 27, 2007 |
| Completion | Oct 24, 2007 |
| First posted | Apr 5, 2007 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: